VivoSeq
Metabolic & Endocrine

Endogenous Cushing's Syndrome

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Endogenous Cushing's Syndrome is an early-stage landscape with 0 programs across 4 companies. The most active players are Corcept Therapeutics, RECORDATI GROUP, Millendo Therapeutics US, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Corcept Therapeutics

0 programs

PreclinicalR

RECORDATI GROUP

0 programs

PreclinicalM

Millendo Therapeutics US, Inc.

0 programs

PreclinicalH

HRA Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed7 · 70%
Active, not recruiting1 · 10%
Terminated1 · 10%
Unknown status1 · 10%

Clinical Trials

Trial Activity

10 trials

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
Active, not recruiting·RRECORDATI GROUP·N/A·NCT05382156·206 enrolled
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
Completed·CCortendo AB·Phase 3·NCT03277690·84 enrolled
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
Completed·RRECORDATI GROUP·Phase 2·NCT03606408·127 enrolled
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Completed·CCorcept Therapeutics·Phase 3·NCT00936741·30 enrolled
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Completed·CCorcept Therapeutics·Phase 3·NCT01371565·4 enrolled
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
Completed·HHRA Pharma·Phase 3·NCT02297945·50 enrolled
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Completed·CCorcept Therapeutics·Phase 3·NCT00569582·50 enrolled
Treatment for Endogenous Cushing's Syndrome
Completed·CCortendo AB·Phase 3·NCT01838551·94 enrolled
A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
Terminated·MMillendo Therapeutics US, Inc.·Phase 2·NCT03053271·4 enrolled
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
Unknown status·—·Phase 4·NCT06131580·7 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)